Third, most inhibitors of NLRP3, NF-B, autophagy, ferroptosis, or senescence remain preclinical and lack regulatory approval, and there is a paucity of validated pharmacodynamic biomarkers in humans (e.g., CSF IL-1/IL-18, GSDMD-N, ex vivo NLRP3 assays) to confirm target engagement
Wound Healing Acceleration and Quality Animal studies demonstrate remarkable wound healing acceleration
topical human work is confined to 0.11% formulations in cosmetic trials UK delivery is free and tracked
Biochim Biophys Acta 1797:113848
Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts
The primary dose-limiting adverse effect associated with CsA is nephrotoxicity, typically manifested as a reversible decrease in the glomerular filtration rate (Shen et al., 2010)